{"id":"W4297094017","doi":"10.1200/jco.22.00533","title":"Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sanofi Pasteur; Pharmacyclics; EMD Serono; Genentech; Aptitude Health; Qbiotics; Italfarmaco; Eli Lilly and Company; Ono Pharmaceutical; Eisai; Astellas Pharma; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Calithera Biosciences; Pfizer; Incyte; Array BioPharma; Five Prime Therapeutics; Ipsen; Clovis Oncology; Les Laboratories Pierre Fabre; Sun Pharma; Advanced Accelerator Applications; Regeneron Pharmaceuticals; Endocyte; Sanofi; GlaxoSmithKline; Amgen; Celgene; EUSA Pharma; AstraZeneca; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Hazard ratio; Internal medicine; Adjuvant; Population; Melanoma; Adjuvant therapy; Adverse effect; Randomized controlled trial; Stage (stratigraphy); Gastroenterology; Oncology; Surgery; Cancer; Immunotherapy; Confidence interval; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009230386,0.0005622896,0.00126338,0.0002680161,0.0002180204,0.000664321,0.00041038,0.0006523327,0.002955687],"category_scores_gemma":[0.0008750086,0.0003016916,0.001111482,0.0001841709,0.0003537221,0.0004030124,0.0002501899,0.001405351,0.0004220112],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007074219,"about_ca_system_score_gemma":0.0008485326,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006446581,"about_ca_topic_score_gemma":0.002194564,"domain_scores_codex":[0.9997327,0.0001358494,0.00001970479,0.00005102132,0.00002158141,0.00003915475],"domain_scores_gemma":[0.9996328,0.0001015932,0.00008330773,0.00001962496,0.00001565564,0.0001470039],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8955423,0.007684489,0.005708702,0.0007811374,0.001428104,0.0000682152,0.00007913735,0.001160362,0.007263923,0.0001510444,0.001790599,0.07834195],"study_design_scores_gemma":[0.5986013,0.3601599,0.02910488,0.0001830094,0.002367029,0.000251394,0.00005078344,0.003229632,0.00285623,0.0002100616,0.002948632,0.00003709307],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945506,0.003505266,0.0001454423,0.0002316118,0.000183302,0.0002487115,0.0001619298,0.00002911265,0.0009439893],"genre_scores_gemma":[0.9967074,0.001137245,0.0003971136,0.0003246754,0.0001356075,0.0002274397,0.0002931129,0.000004517358,0.0007729436],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002955687,"threshold_uncertainty_score":0.009887695,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08196171607296819,"score_gpt":0.3946335868003538,"score_spread":0.3126718707273856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}